Congenital Syphilis: An Emerging, Preventable Public Health Crisis
Clinical Chemistry · 2024
DOI: 10.1093/clinchem/hvae042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Fnu Sapna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, United States. Hauptthemen laut MEDLINE: Syphilis, Congenital. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Syphilis is a sexually transmitted infection caused by the bacterium Treponema pallidum. Congenital syphilis (CS) occurs by transplacental infection or during birth via direct contact with infected maternal lesions. Congenital syphilis may result in serious neonatal conditions, including adverse birth outcomes, hepatosplenomegaly, anemia, jaundice, and failure to thrive. While syphilis may be asymptomatic in infants at birth, a significant number of untreated children experience late-stage manifestations such as neurologic disorders and developmental delays. Despite the declining rates of the vertical transmission of infections such as HIV and hepatitis B, CS continues to remain a global concern. Over the past 2 decades, there has been a significant rise in the global incidence of CS. In the United States, there has been a substantial increase in reported CS cases, with a 200% rise from 941 cases in 2017 to 2855 cases in 2021 (1). In 2022, 88% of congenital syphilis cases were attributed to a lack of timely testing and adequate treatment during pregnancy (2). Over 37% of infants with CS were born to individuals who may not have had access to prenatal screening and care. To minimize perinatal transmission of syphilis, the CDC recommends syphilis screening during the first prenatal care visit or, in cases where access to prenatal care is limited, promptly upon confirmation of pregnancy (3). Effective screening for syphilis during pregnancy has demonstrated efficacy in preventing syphilis-related morbidity (3). Furthermore, to successfully tackle the rise in CS cases, it is imperative to appreciate the diverse socioeconomic and behavioral components contributing to the increase in maternal syphilis rates. The spike in CS cases in Mississippi, for instance, mirrored a rapid surge in newborn hospitalizations linked to maternal substance use, underscoring the intertwining of 2 public health epidemics (4). Apart from enhancing access to prenatal care, strategies for delivering care beyond clinical settings are essential for ensuring appropriate and timely screening and treatment. In resource-constrained settings, the utilization of point-of-care testing holds significant promise in enhancing healthcare delivery. Recognizing this potential, the World Health Organization (WHO) has recommended dual HIV and syphilis point-of-care tests as the first antenatal screening method for pregnant women. This recommendation aims to improve testing capacity and promote equitable access. Notably, rates of HIV testing are higher compared to syphilis testing in many countries, and the adoption of dual point-of-care testing is anticipated to improve the uptake of syphilis testing (5). To curb the transmission of syphilis during pregnancy, it is crucial to continue to identify contributing factors and implement policies, testing guidelines, and risk mitigation strategies. Furthermore, it is necessary to ensure adequate funding for antenatal screening and testing, including rapid point-of-care testing in remote or rural areas. Finally, the establishment of robust health information systems to promptly notify public health authorities of testing results will improve surveillance and linkage to care. The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Upon manuscript submission, all authors completed the author disclosure form. None declared. K. Balogun has received a research grant from the Academy of Clinical Laboratory Physicians and Scientists (ACLPS) and financial support for attending the American Society for Clinical Pathology (ASCP) meeting. K. Balogun serves on the ADLM's Society for Young Clinical Laboratorians Core Committee, Nutrition, and Clinical Translational Science Divisions, and the ACLPS Education Committee.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, United States.
- Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, United States.
Zitieren
APA
Sapna, F., & Balogun, K. (2024). Congenital Syphilis: An Emerging, Preventable Public Health Crisis. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae042
Vancouver
Sapna F, Balogun K. Congenital Syphilis: An Emerging, Preventable Public Health Crisis. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvae042
BibTeX
@article{Sapna2024,
author = {Sapna, Fnu and Balogun, Kayode},
title = {Congenital Syphilis: An Emerging, Preventable Public Health Crisis},
journal = {Clinical Chemistry},
year = {2024},
doi = {10.1093/clinchem/hvae042}
}
EUVIMED